Currently Enrolling
Interventional

The FIRSTx Trial for FSGS Patients

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Brief Description

FIRSTx is a Phase 2 study testing the safety and effectiveness of an investigational drug called CXA-10 designed to treat FSGS without steroids.

Study Coordinator

Tetyana Vasylyeva

Email Phone 806-236-0320
Site Name

Texas Tech University
1400 Coulter St, Amarillo, TX 79106

Sponsor

Complexa, Inc.

Study Drug

CXA-10

Estimated enrollment

30

Estimated end date

July, 2019

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Currently Enrolling
Interventional

The FIRSTx Trial for FSGS Patients

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Brief Description

FIRSTx is a Phase 2 study testing the safety and effectiveness of an investigational drug called CXA-10 designed to treat FSGS without steroids.

Trial for people with

Primary Focal Segmental Glomerulosclerosis (FSGS)

Study Goal

This study will see if CXA-10 can reduce proteinuria while maintaining stable kidney function in people with FSGS.

What is involved for the Patient?

Throughout the course of the study, researchers will measure how different doses of CXA-10 impact proteinuria and carefully evaluate the kidney related and other effects of CXA-10. CXA-10 will be provided to study participants in the form of a pill taken once a day in the morning with food.

About the drug or intervention

CXA-10 appears to work by reducing inflammation in the glomeruli and helping to prevent scarring. CXA-10 has been evaluated in healthy volunteers.

Amarillo, TX
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

See other frequently asked questions